The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Alemtuzumab Induction in Renal Transplantation
Abstract
BACKGROUND: There are few comparisons of antibody induction therapy allowing early glucocorticoid withdrawal in renal-transplant recipients. The purpose of the present study was to compare induction therapy involving alemtuzumab with the most commonly used induction regimens in patient populations at either high immunologic risk or low immunologic risk. METHODS: In this prospective study, we randomly assigned patients to receive alemtuzumab or conventional induction therapy (basiliximab or rabbit antithymocyte globulin). Patients were stratified according to acute rejection risk, with a high risk defined by a repeat transplant, a peak or current value of panel-reactive antibodies of 20% or more, or black race. The 139 high-risk patients received alemtuzumab (one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilogram of body weight given over 4 days, in 69 patients). The 335 low-risk patients received alemtuzumab (one dose of 30 mg, in 164 patients) or basiliximab (a total of 40 mg over 4 days, in 171 patients). All patients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocorticoid taper in a regimen of early steroid withdrawal. The primary end point was biopsy-confirmed acute rejection at 6 months and 12 months. Patients were followed for 3 years for safety and efficacy end points. RESULTS: The rate of biopsy-confirmed acute rejection was significantly lower in the alemtuzumab group than in the conventional-therapy group at both 6 months (3% vs. 15%, P<0.001) and 12 months (5% vs. 17%, P<0.001). At 3 years, the rate of biopsy-confirmed acute rejection in low-risk patients was lower with alemtuzumab than with basiliximab (10% vs. 22%, P=0.003), but among high-risk patients, no significant difference was seen between alemtuzumab and rabbit antithymocyte globulin (18% vs. 15%, P=0.63). Adverse-event rates were similar among all four treatment groups. CONCLUSIONS: By the first year after transplantation, biopsy-confirmed acute rejection was less frequent with alemtuzumab than with conventional therapy. The apparent superiority of alemtuzumab with respect to early biopsy-confirmed acute rejection was restricted to patients at low risk for transplant rejection; among high-risk patients, alemtuzumab and rabbit antithymocyte globulin had similar efficacy. (Funded by Astellas Pharma Global Development; INTAC ClinicalTrials.gov number, NCT00113269.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Brennan, D. C., Daller, J. A., Lake, K. D., Cibrik, D., & Del Castillo, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060068 · Cited by 742
LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS
ALMOND, P. S., MATAS, A., GILLINGHAM, K., DUNN, D. L., PAYNE, W. D., NAJARIAN, J. S., PAUL, G., & RAINER, G. (1993) · Transplantation · doi:10.1097/00007890-199304000-00013 · Cited by 660
Woodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
Self-citationCAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS
Calne, R., Moffatt, S. D., Friend, P. J., Jamieson, N. V., Bradley, J. A., Hale, G., Firth, J., Bradley, J. R., Smith, K. G. C., & Waldmann, H. (1999) · Transplantation · doi:10.1097/00007890-199911270-00032 · Cited by 305
&NA; (1999) · Transplantation · doi:10.1097/00007890-199912270-00009 · Cited by 277
Ciancio, G., Burke, G. W., Gaynor, J. J., Carreno, M. R., Cirocco, R. E., Mathew, J. M., Mattiazzi, A., Cordovilla, T., Roth, D., Kupin, W., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000165847.05787.08 · Cited by 220
Vanrenterghem, Y., Lebranchu, Y., Hen??, R., Oppenheimer, F., & Ekberg, H. (2000) · Transplantation · doi:10.1097/00007890-200011150-00015 · Cited by 213
Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients
Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101037 · Cited by 199
Kaufman, D. B., Leventhal, J. R., Axelrod, D., Gallon, L. G., Parker, M. A., & Stuart, F. P. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01067.x · Cited by 186
Self-citation
Cited by
Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., et al. (2012) · JAMA · doi:10.1001/jama.2012.316 · Cited by 553
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
Hill, P., Cross, N. B., Barnett, A. N. R., Palmer, S. C., & Webster, A. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004759.pub2 · Cited by 135
Muehlenbachs, A., Nabasumba, C., McGready, R., Turyakira, E., Tumwebaze, B., Dhorda, M., Nyehangane, D., Nalusaji, A., Nosten, F., Guerin, P. J., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-150 · Cited by 35
Metadata
- Authors
- Hanaway, M. J., Woodle, E. S., Mulgaonkar, S., Peddi, V. R., Kaufman, D. B., First, M. R., Croy, R., & Holman, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127536951
- Cited by
- 383
- References
- 15
- FWCI
- 29.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alemtuzumab Induction in Renal Transplantation. https://app.cochat.ai/papers/10.1056/nejmoa1009546
- The paper
- Hanaway, M. J., Woodle, E. S., Mulgaonkar, S., Peddi, V. R., Kaufman, D. B., First, M. R., Croy, R., & Holman, J. (2011). Alemtuzumab Induction in Renal Transplantation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1009546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.